Impact of Major Cardiovascular Risk Factors on the Incidence of Cardiovascular Disease among Overweight and Non-Overweight Individuals: The Circulatory Risk in Communities Study (CIRCS)

Takumi Matsumura1, 2, Tomoko Sankai3, Kazumasa Yamagishi4, 5, Yasuhiko Kubota2, Mina Hayama-Terada2, 6, Isao Muraki1, Mitsumasa Umesawa4, 7, Renzhe Cui1, Hironori Imano1, Tetsuya Ohira8, Akihiko Kitamura9, Takeo Okada2, Masahiko Kiyama2 and Hiroyasu Iso1, 4

1 Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
2 Osaka Center for Cancer and Cardiovascular Disease Prevention, Osaka, Japan
3 Department of Public Health and Nursing, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
4 Department of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba, Ibaraki, Japan
5 Ibaraki Western Medical Center, Ibaraki, Japan
6 Yao City Public Health Center, Osaka, Japan
7 School of Medicine, Dokkyo University, Tochigi, Japan
8 Department of Epidemiology, School of Medicine, Fukushima Medical University, Fukushima, Japan
9 Research Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

Aim: We aimed to examine the impact of high-risk levels of cardiovascular risk factors on the incidence of cardiovascular disease (CVD) in overweight and non-overweight individuals without treatment for the risk factors.

Methods: A total of 8,051 individuals aged 40–74 years without a history of CVD and/or without treatment for hypertension, diabetes, hyperlipidemia, and kidney disease at baseline in 1995–2000 were followed up for a median of 14.1 years. We classified the participants into three risk categories (low-, intermediate-, and high-risk groups) on the basis of individual risk factors (blood pressure, serum glucose, low-density lipoprotein cholesterol [LDL-C], and urinary protein) according to the guidelines of Japanese clinical societies. The high-risk group (systolic blood pressure $\geq 160$ mmHg or diastolic blood pressure $\geq 100$ mmHg, fasting serum glucose $\geq 130$ mg/dL or non-fasting serum glucose $\geq 180$ mg/dL, LDL-C $\geq 180$ mg/dL, proteinuria $\geq$ 2+) needed to refer to physicians or start treatment immediately. Overweight was defined as a body mass index of $\geq 25$ kg/m².

Results: Compared with those in the non-overweight low-risk group, the hazard ratios (HRs) (95% confidence intervals, population-attributable fractions [PAFs]) of CVD in the high-risk categories of blood pressure were 2.0 (1.4–2.9, 7.0%) in the non-overweight high-risk group and 2.9 (1.9–4.3, 6.8%) in the overweight high-risk group. The corresponding HRs (95% confidence intervals, PAFs) of serum glucose were 2.0 (1.2–3.4, 2.5%) and 2.2 (1.1–4.3, 1.5%) in the non-overweight and overweight high-risk groups, respectively. Such associations were not observed for the high-risk group of LDL-C and proteinuria.

Conclusions: The present long-term observational study implies that targeting persons with non-treated severe hypertension and diabetes is prioritized to prevent CVD regardless of overweight status.

Key words: Risk factor, Cardiovascular disease, Population, Follow-up study, Epidemiology

Introduction

Hypertension, diabetes, dyslipidemia, and chronic kidney disease are known risk factors of cardiovascular disease (CVD)1-5, and the prevention and management of these factors are important for prevention of incident CVD. In 2008, the Japanese government launched a nationwide intervention strategy for prevention of CVD among men and women aged 40–74 years6. This strategy focuses on persons with metabolic syndrome and helps them reduce their risk through health guidance about the
lifestyle modification. If the expected risk is high enough, they were referred to physicians for treatment for the prevention of CVD. However, it has been reported that more than half of Japanese patients who develop CVD had not consulted a physician before the onset\(^7\). Thus, it is necessary to prioritize the intervention for non-treated high-risk individuals with CVD. In this context, the Japan Trial in High-risk Individuals to Accelerate their Referral to Physicians (J-HARP) investigated whether health counseling of non-treated high-risk individuals with CVD accelerated their consultation to physicians\(^8\). It is important to estimate the preventive effect of interventions on non-treated high-risk individuals on the development of CVD. However, epidemiological evidence on the attributable risk of non-treated high-risk individuals with cardiovascular risk factors for the incidence of CVD in Japan has been scant.

Furthermore, previous studies showed that both non-overweight and overweight persons with CVD risk factors had high-risk for CVD and the population-attributable fractions (PAFs) of CVD in non-overweight persons were larger than those in overweight persons\(^9, 10\). However, these studies investigated the impact of accumulation of risk factors on CVD, stratified by overweight status, and that of each risk factor, especially among persons with non-treated CVD risk factors, has not been elucidated. Targeting only overweight persons among non-treated high-risk individuals is probably not enough for effective prevention strategies.

### Aim

In this study, we aimed to calculate the hazard ratios (HRs) and PAFs of incident CVD associated with established risk factors for the high- and intermediate-risk groups, compared with the low-risk group among non-treated individuals, and investigate whether these associations were modified by overweight status.

### Methods

#### Study Population

The study population included residents aged 40–74 years who participated in community health screening between 1995 and 2000 in four sites of the Circulatory Risk in Communities Study (CIRCS)\(^11\); Ikawa, Akita Prefecture; Minami Takayasu District of Yao City, Osaka Prefecture; Noichi, Kochi Prefecture; and Kyowa, Ibaraki Prefecture. The number of persons who participated in the baseline survey was 10,822 (4,099 men and 6,723 women).

#### Baseline Survey

Height was measured with socks on, and weight was measured with the participant wearing light clothing. The BMI at baseline was calculated as weight (kg) divided by the square of height (m\(^2\)). Overweight was defined as a BMI of $\geq 25$ kg/m\(^2\). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in the right arm, using standard epidemiological methods with a standard mercury sphygmomanometer with a 14-cm-wide and 51-cm-long cuff, by a trained physician after the participant has rested for 5 min in the sitting position\(^12\). The measurements were repeated after the participant took five deep breaths if the SBP was $\geq 140$ mmHg or the DBP was $\geq 90$ mmHg. In the present study, the first reading was used for blood pressure levels. Dipstick urinalysis was performed with spontaneously voided fresh urine to assess proteinuria.

Blood was drawn from seated participants, and serum was immediately separated. Serum glucose was measured using the glucokinase method; total cholesterol (TC) was measured using an enzymatic assay; high-density lipoprotein cholesterol (HDL-C) was measured with a dextran sulfate-phosphotungstate-MgCl\(_2\) precipitation method; and triglyceride (TG) was measured using an enzymatic assay for free glycerol with a Hitachi 7250 autoanalyzer (Hitachi Medical, Tokyo, Japan) at the laboratory of the Osaka Center for Cancer and Cardiovascular Disease Prevention, which is an international member of the US National Cholesterol Reference Method Laboratory Network\(^13-15\). Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula, as follows: $\text{LDL-C (mg/dL)} = \text{TC (mg/dL)} - \text{HDL-C (mg/dL)} - (\text{TG (mg/dL)} / 5)^{16}$. In this study, 67% of the participants were non-fasting. As a previous study reported that LDL-C calculated using the Friedewald formula and values measured using direct methods as the gold standard were comparable only when TG is $<781$ mg/dL at both fasting and non-fasting conditions\(^9\), we excluded participants with TG $\geq 781$ mg/dL.

Smoking status, number of cigarettes smoked per
day, usual alcohol intake per day, family history of CVD, and use of medication for hypertension, diabetes, hyperlipidemia, and kidney disease were ascertained through interviews.

Definition of Risk Categories
As shown in Table 1, we classified the participants into three risk categories for each risk factor (blood pressure, serum glucose, LDL-C, and urinary protein) according to the J-HARP criteria(a), which defined high-risk individuals (basically levels of immediate need to consult a physician) on the basis of the guidelines of clinical societies in Japan(b-d). Participants who were receiving treatment for hypertension, diabetes, hyperlipidemia, or kidney disease were excluded.

Follow-Up Survey of the Incidence of CVD
The incidence of CVD was surveyed from the time of the baseline survey until the end of 2013 for Ikawa, 2012 for Minami Takayasu, 2011 for Kyowa, and 2007 for Noichi. CVD included stroke and coronary heart disease (CHD). CHD included myocardial infarction (MI), definite angina pectoris, and sudden cardiac death. To systematically catch cases of incident stroke and CHD in the CIRCS communities, the municipal governments of these communities, collaborating with the CIRCS investigators, launched a systematic community stroke and CHD registration system. Details of the system were described elsewhere(e). Briefly, the possible incident CVD case was extracted on the basis of at least one of the following sources: death certificate; national health insurance claim; reports from local physicians, public health nurses, and community health volunteers (neighbors); cardiovascular risk surveys; and/or household visit surveys. To make the diagnosis of CVD, participants or their families were contacted by telephone, visited, or invited to obtain the history of incidence. We also reviewed the medical records of local clinics and hospitals. Stroke was diagnosed when a sudden onset occurred and when neurological symptoms have persisted for at least 24 h after onset or until death. We reviewed computed tomography (CT) and/or magnetic resonance imaging (MRI) scans to confirm the diagnosis of stroke subtype. CT and MRI data were available for approximately 92% of the stroke cases. The diagnostic criteria of CHD were based on modified World Health Organization criteria(g). MI was diagnosed according to the following two conditions: (1) typical severe chest pain persisting for ≥ 30 min and (2) appearance of abnormal Q or QS wave on the electrocardiogram, or a consistent change in the myocardial enzyme level. If symptom (1) was observed but finding (2) was not, we diagnosed possible MI. Definite angina pectoris was diagnosed in the presence of repeated episodes of chest pain during effort, especially when walking, usually rapidly disappearing after the cessation of effort or with the use of sublingual nitroglycerin. If the person died within 24 h from onset except with MI and angina pectoris as causes, it was considered sudden cardiac death. Finally, several physicians blinded to the baseline data determined the incidence of stroke or CHD by reviewing available information.

Table 1. Classification of participants into three risk categories for each risk factor at the baseline survey

| Risk Factor       | Low-risk group | Intermediate-risk group | High-risk group |
|-------------------|----------------|-------------------------|-----------------|
| Blood pressure    | SBP < 140 mmHg and DBP < 90 mmHg | The persons with neither low risk group nor high-risk group | SBP ≥ 160 mmHg or DBP ≥ 100 mmHg |
| Serum glucose     | Fasting serum glucose < 110 mg/dL or Non-fasting serum glucose < 140 mg/dL | 110 ≤ Fasting serum glucose < 130 mg/dL or 140 ≤ Non-fasting serum glucose < 180 mg/dL | Fasting serum glucose ≥ 130 mg/dL or Non-fasting serum glucose ≥ 180 mg/dL |
| LDL-C             | LDL-C < 140 mg/dL | 140 ≤ LDL-C < 180 mg/dL | LDL-C ≥ 180 mg/dL |
| Proteinuria       | – or ± | 1+ | ≥ 2+ |

SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol.
We previously reported that LDL-C calculated using the Friedewald formula is applicable to persons with TG \(\leq 781\) mg/dL, although the Friedewald formula is recommended for persons with TG \(\leq 400\) mg/dL. For confirmation, we conducted a sensitivity analysis excluding participants with TG \(\geq 400\) mg/dL.

SAS (version 9.4; SAS Institute, Cary, NC, USA) was used for all analyses. All statistical analyses were performed using a two-tailed test, and \(P<0.05\) was considered statistically significant.

**Ethical Considerations**

Informed consent was obtained from representatives in communities and was implied by individual participation in health checkups, on the basis of the guidelines of the Council for International Organizations of Medical Science. This study was approved by the Ethics Committee of the Osaka Center for Cancer and Cardiovascular Disease Prevention, Osaka University and the University of Tsukuba.

**Results**

After the follow-up for 109,294 person-years (median 14.1 years), we confirmed 327 incident cases of CVD (188 in men and 139 in women), including 223 stroke cases (117 in men and 106 in women) and 111 CHD cases (76 in men and 35 in women).

**Table 2.** Baseline characteristics for study population without clinical treatment, stratified by developing cardiovascular disease (CVD) or remaining free of CVD

|                         | CVD     | Free of CVD | \(P\) value |
|-------------------------|---------|-------------|-------------|
| No. at risk             | 327     | 7724        |             |
| Age, years              | 62.3 (8.5) | 56.1 (9.2)   | \(<0.001\)   |
| Women, %                | 42.5    | 64.1        | \(<0.001\)   |
| BMI, kg/m\(^2\)         | 23.5 (3.2) | 23.2 (3.1)   | \(0.09\)     |
| SBP, mmHg               | 142.0 (21.0) | 132.6 (19.5) | \(<0.001\)   |
| DBP, mmHg               | 85.0 (12.1) | 80.3 (11.6)   | \(<0.001\)   |
| Fasting serum glucose, mg/dL (\(n=2,678\)) | 101.4 (24.1) | 96.7 (16.9)   | \(0.006\)     |
| Non-fasting serum glucose, mg/dL (\(n=5,373\)) | 121.3 (56.3) | 106.5 (31.0) | \(<0.001\)     |
| TG, mg/dL               | 139.2 (80.0) | 119.7 (71.6) | \(<0.001\)   |
| LDL-C, mg/dL            | 124.8 (31.8) | 126.0 (33.0) | 0.51         |
| HDL-C, mg/dL            | 55.3 (15.6) | 58.8 (14.5)   | \(<0.001\)   |
| Proteinuria \(\geq +\), % | 2.5     | 1.3         | 0.08         |
| Current smoker, %       | 34.7    | 22.2        | \(<0.001\)   |
| Current drinker, %      | 41.4    | 36.1        | 0.05         |
| Family history of CVD, % | 36.7    | 30.1        | 0.01         |

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

was calculated as the duration until the occurrence of CVD, death, or failure to follow-up, whichever occurred first. During follow-up, 380 (4.7%) participants moved out of their community. Baseline characteristics were compared between participants with or without CVD using a t-test or chi-square test. We calculated the HRs and 95% confidence intervals (CIs) of CVD according to three risk categories of each risk factor using Cox proportional hazards models with reference to the low-risk group. In model 1, we adjusted for age (years), sex, and area. In model 2, we further adjusted for BMI (non-overweight \(<25\) kg/m\(^2\) and overweight \(\geq 25\) kg/m\(^2\)), smoking status (never, former, current smoker \(<20\) and \(\geq 20\) cigarettes per day), alcohol intake (never, former, current drinker \(<23, 23–<46, 46–<69, and \geq 69\) g/day), family history of CVD, and other conventional risk factors of CVD (blood pressure, serum glucose, LDL-C, HDL-C, TG, and proteinuria). The linear trend for HRs across the three risk categories was tested using an order variable (0, 1, and 2 for three risk categories). We calculated the PAF with the following formula: PAF = pd \(\times (HR - 1)/HR\), where pd is the ratio of the incidence of each risk category to the total incidence and HR is the multivariate HR of each risk category with 95% CI for PAFs. We further stratified the participant according to non-overweight or overweight status and calculated the HRs (95% CIs) and PAFs of CVD according to three risk categories of each risk factor with reference to the non-overweight low-risk group.

We previously reported that LDL-C calculated using the Friedewald formula is applicable to persons with TG \(\leq 781\) mg/dL, although the Friedewald formula is recommended for persons with TG \(\leq 400\) mg/dL. For confirmation, we conducted a sensitivity analysis excluding participants with TG \(\geq 400\) mg/dL.

SAS (version 9.4; SAS Institute, Cary, NC, USA) was used for all analyses. All statistical analyses were performed using a two-tailed test, and \(P<0.05\) was considered statistically significant.
blood pressure and serum glucose, respectively. The intermediate- and high-risk groups of blood pressure had higher risk of stroke, with HRs (95% CIs, PAFs) of 1.8 (1.3–2.5, 15.4%) in the intermediate-risk group and 2.8 (2.0–4.0, 18.0%) in the high-risk group. The HRs and PAFs of CHD were statistically significant in the intermediate-risk group of blood pressure [HR (95% CI), PAF: 1.5 (1.0–2.4), 12.0%] and high-risk group of serum glucose [HR (95% CI), PAF: 2.9 (1.6–5.3), 7.1%]. There was an interaction of borderline significance between overweight and blood pressure (P for interaction 0.07), serum glucose (P for interaction 0.06) and LDL-C (P for interaction 0.05) in relation to stroke, and LDL-C (P for interaction 0.08) in relation to CHD.

After participants were stratified by non-overweight or overweight status, the high-risk group of blood pressure and serum glucose had a higher risk of CVD in both non-overweight and overweight participants (Table 4). Furthermore, the HRs and PAFs of incident CVD according to the high-risk categories of blood pressure and serum glucose were not different between the non-overweight and overweight groups when we used the non-overweight low-risk group as reference (Table 4). According to the risk categories of blood pressure, the multivariable HRs (95% CIs, PAFs) of CVD were 2.0 (1.5–2.6, 12.5%) in the non-overweight intermediate-risk
| CVD                      | Low       | Intermediate | High       | \(P_{\text{for trend}}\) |
|--------------------------|-----------|--------------|------------|--------------------------|
| **Blood pressure**       |           |              |            |                          |
| Person-years             | 69356     | 26642        | 13295      |                          |
| No. at risk              | 5030      | 2006         | 1015       |                          |
| No. of cases             | 135       | 113          | 79         |                          |
| Age-, sex- and area-adjusted HR | 1.0 | 1.7 (1.3-2.2) | 2.3 (1.8-3.1) | < 0.001 |
| Multivariable HR         | 1.0       | 1.7 (1.3-2.2) | 2.3 (1.7-3.1) | < 0.001 |
| PAF (%)                  | -         | 14.5 (8.7 to 19.1) | 13.7 (10.2 to 16.3) |            |
| **Serum glucose**        |           |              |            |                          |
| Person-years             | 99461     | 6806         | 3027       |                          |
| No. at risk              | 7272      | 538          | 241        |                          |
| No. of cases             | 268       | 34           | 25         |                          |
| Age-, sex- and area-adjusted HR | 1.0 | 1.3 (0.9-1.8) | 2.3 (1.5-3.4) | < 0.001 |
| Multivariable HR         | 1.0       | 1.2 (0.8-1.7) | 2.1 (1.4-3.1) | 0.002 |
| PAF (%)                  | -         | 1.5 (-2.5 to 4.2) | 3.9 (2.0 to 5.2) |            |
| **LDL-C**                |           |              |            |                          |
| Person-years             | 74054     | 28857        | 6383       |                          |
| No. at risk              | 5509      | 2086         | 456        |                          |
| No. of cases             | 229       | 83           | 15         |                          |
| Age-, sex- and area-adjusted HR | 1.0 | 1.0 (0.8-1.3) | 0.9 (0.5-1.5) | 0.69 |
| Multivariable HR         | 1.0       | 1.0 (0.8-1.3) | 0.9 (0.5-1.5) | 0.69 |
| PAF (%)                  | -         | -0.4 (-8.0 to 5.5) | -0.6 (-4.3 to 1.5) |            |
| **Proteinuria**          |           |              |            |                          |
| Person-years             | 107925    | 948          | 421        |                          |
| No. at risk              | 7943      | 73           | 35         |                          |
| No. of cases             | 319       | 5            | 3          |                          |
| Age-, sex- and area-adjusted HR | 1.0 | 1.6 (0.7-3.9) | 1.9 (0.6-6.1) | 0.13 |
| Multivariable HR         | 1.0       | 1.2 (0.5-2.9) | 1.6 (0.5-5.0) | 0.41 |
| PAF (%)                  | -         | 0.2 (-1.7 to 1.0) | 0.3 (-0.9 to 0.7) |            |
| **Stroke**               |           |              |            |                          |
| **Blood pressure**       |           |              |            |                          |
| No. of cases             | 84        | 77           | 62         |                          |
| Age-, sex- and area-adjusted HR | 1.0 | 1.9 (1.4-2.5) | 2.9 (2.1-4.1) | < 0.001 |
| Multivariable HR         | 1.0       | 1.8 (1.3-2.5) | 2.8 (2.0-4.0) | < 0.001 |
| PAF (%)                  | -         | 15.4 (8.2 to 20.6) | 18.0 (14.0 to 20.8) |            |
| **Serum glucose**        |           |              |            |                          |
| No. of cases             | 182       | 28           | 13         |                          |
| Age-, sex- and area-adjusted HR | 1.0 | 1.6 (1.1-2.4) | 1.8 (1.0-3.2) | 0.004 |
| Multivariable HR         | 1.0       | 1.4 (0.9-2.1) | 1.6 (0.9-2.8) | 0.03 |
| PAF (%)                  | -         | 3.7 (-0.8 to 6.7) | 2.1 (-0.7 to 3.8) |            |
| **LDL-C**                |           |              |            |                          |
| No. of cases             | 163       | 51           | 9          |                          |
| Age-, sex- and area-adjusted HR | 1.0 | 0.8 (0.6-1.1) | 0.8 (0.4-1.5) | 0.19 |
| Multivariable HR         | 1.0       | 0.8 (0.6-1.2) | 0.7 (0.3-1.4) | 0.14 |
| PAF (%)                  | -         | -4.7 (-15.2 to 3.0) | -1.9 (-7.7 to 1.0) |            |
| **Proteinuria**          |           |              |            |                          |
| No. of cases             | 217       | 4            | 2          |                          |
| Age-, sex- and area-adjusted HR | 1.0 | 1.9 (0.7-3.1) | 1.9 (0.5-7.8) | 0.14 |
| Multivariable HR         | 1.0       | 1.4 (0.5-3.9) | 1.4 (0.3-5.8) | 0.44 |
| PAF (%)                  | -         | 0.5 (-1.7 to 1.3) | 0.3 (-1.7 to 0.7) |            |
LDL-C, the HR and PAF for CHD were statistically significant only in the intermediate-risk group with non-overweight. These results did not change substantially when we excluded the participants with non-fasting blood sample (33% of total participants were at fasting; Supplemental Tables 1 and 2) and those with TG ≥ 400 mg/dL (data not shown).

Discussion

In our long-term prospective cohort study of the general population, we found a twofold excess risk of incident CVD associated with the non-treated high-risk categories of blood pressure and serum glucose. Among the four cardiovascular risk factors, high blood pressure had the largest impact of incident CVD and stroke, and high serum glucose had the largest impact of incident CHD. When we stratified participants by overweight status, the HRs and PAFs of incident stroke associated with high blood pressure did not differ materially between the non-overweight and overweight groups although they were not statistically significant for incident CHD in all risk categories. According to the risk categories of serum glucose, the corresponding HRs (95% CIs, PAFs) were 1.5 (1.0–2.2, 2.6%), 2.0 (1.2–3.4, 2.5%), 1.1 (0.8–1.4, 1.7%), 0.7 (0.3–1.5, −1.0%), and 2.2 (1.1–4.3, 1.5%) in the non-overweight intermediate-risk, non-overweight high-risk, overweight low-risk, overweight intermediate-risk, and overweight high-risk groups, respectively.

In the risk categories of blood pressure, the HRs and PAFs of incident stroke associated with high blood pressure did not differ materially between the non-overweight and overweight groups although they were not statistically significant for incident CHD in all risk categories. In the risk categories of serum glucose, the HRs and PAFs of stroke were statistically significant in the intermediate- and high-risk groups with non-overweight, but not in any risk groups with overweight. Those for CHD were statistically significant only in the high-risk group of serum glucose with overweight. In the risk categories of LDL-C, the HR and PAF for CHD were statistically significant only in the intermediate-risk group with non-overweight.

These results did not change substantially when we excluded the participants with non-fasting blood sample (33% of total participants were at fasting; Supplemental Tables 1 and 2) and those with TG ≥ 400 mg/dL (data not shown).

**Table 3**

| Risk Factor | Low | Intermediate | High | P for trend |
|-------------|-----|--------------|------|-------------|
| CHD         |     |              |      |             |
| Blood pressure |     |              |      |             |
| No. of cases | 54  | 38           | 19   |             |
| Age-, sex- and area-adjusted HR | 1.0 | 1.4 (0.9–2.2) | 1.4 (0.8–2.3) | 0.13 |
| Multivariable HR | 1.0 | 1.5 (1.0–2.4) | 1.4 (0.8–2.4) | 0.10 |
| PAF (%)    | -   | 12.0 (0.1 to 19.8) | 4.8 (-3.9 to 9.9) |
| Serum glucose |     |              |      |             |
| No. of cases | 91  | 8            | 12   |             |
| Age-, sex- and area-adjusted HR | 1.0 | 0.8 (0.4–1.7) | 2.9 (1.6–5.4) | 0.01 |
| Multivariable HR | 1.0 | 0.8 (0.4–1.7) | 2.9 (1.6–5.3) | 0.01 |
| PAF (%)    | -   | -1.7 (-11.3 to 2.9) | 7.1 (3.9 to 8.8) |
| LDL-C      |     |              |      |             |
| No. of cases | 71  | 34           | 6    |             |
| Age-, sex- and area-adjusted HR | 1.0 | 1.5 (1.0–2.2) | 1.6 (0.7–3.7) | 0.06 |
| Multivariable HR | 1.0 | 1.4 (0.9–2.1) | 1.4 (0.6–3.2) | 0.15 |
| PAF (%)    | -   | 8.2 (-3.5 to 15.9) | 1.5 (-3.9 to 3.7) |
| Proteinuria |     |              |      |             |
| No. of cases | 109 | 1            | 1    |             |
| Age-, sex- and area-adjusted HR | 1.0 | 0.9 (0.1–6.2) | 1.9 (0.3–13.4) | 0.67 |
| Multivariable HR | 1.0 | 0.7 (0.1–5.0) | 2.0 (0.3–15.0) | 0.76 |
| PAF (%)    | -   | -0.4 (-8.6 to 0.7) | 0.5 (-2.4 to 0.8) |

CHD, coronary heart disease; HR, hazard ratio; PAF, population-attributable fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol. Multivariable HRs were adjusted for age, sex, body mass index, smoking status, alcohol intake, family history of CVD, and the above-mentioned other conventional risk factors (blood pressure, serum glucose, LDL-C, high-density lipoprotein cholesterol, triglyceride, and proteinuria).
Table 4. Hazard ratios and population-attributable fractions (95% confidence intervals) of incident cardiovascular disease (CVD) according to each risk factor category among men and women without clinical treatment, stratified by overweight status

| Risk Factor | Non-overweight (BMI < 25 kg/m²) | Overweight (BMI ≥ 25 kg/m²) |
|-------------|---------------------------------|------------------------------|
|             | Low | Intermediate | High | Low | Intermediate | High |
| CVD         |     |              |      |     |              |      |
| Blood pressure |     |              |      |     |              |      |
| Person-years | 55173 | 17831       | 8378 | 14184 | 8811        | 4917  |
| No. at risk  | 4004 | 1355        | 644  | 1026 | 651          | 371   |
| No. of cases | 104  | 84          | 45   | 31   | 29           | 34    |
| Age-, sex- and area-adjusted HR |      |              |      |      |              |      |
| Blood pressure | 1.0 | 1.9 (1.4-2.6) | 2.1 (1.5-2.9) | 1.2 (0.8-1.8) | 1.5 (1.0-2.2) | 3.1 (2.1-4.6) |
| Multivariable HR | 1.0 | 2.0 (1.5-2.6) | 2.0 (1.4-2.9) | 1.1 (0.7-1.6) | 1.3 (0.9-2.0) | 2.9 (1.9-4.3) |
| PAF (%) | 12.5 (8.1 to 15.9) | 7.0 (4.1 to 9.0) | 0.6 (-3.9 to 3.6) | 2.2 (-1.3 to 4.5) | 6.8 (5.0 to 8.0) |
| Serum glucose |     |              |      |     |              |      |
| Person-years | 74902 | 4484        | 1996 | 24559 | 2322        | 1031  |
| No. at risk  | 5485 | 357         | 161  | 1787 | 181         | 80    |
| No. of cases | 190  | 27          | 16   | 78   | 7           | 9     |
| Age-, sex- and area-adjusted HR | 1.0 | 1.6 (1.0-2.3) | 2.3 (1.4-3.8) | 1.3 (1.0-1.7) | 0.9 (0.4-2.0) | 2.8 (1.4-5.4) |
| Multivariable HR | 1.0 | 1.5 (1.0-2.2) | 2.0 (1.2-3.4) | 1.1 (0.8-1.4) | 0.7 (0.3-1.5) | 2.2 (1.1-4.3) |
| PAF (%) | 2.6 (-0.2 to 4.5) | 2.5 (0.9 to 3.5) | 1.7 (-5.4 to 7.1) | -1.0 (-4.6 to 0.7) | 1.5 (0.3 to 2.1) |
| LDL-C       |     |              |      |     |              |      |
| Person-years | 57085 | 19837       | 4460 | 16968 | 9020        | 1923  |
| No. at risk  | 4244 | 1444        | 315  | 1265 | 642         | 141   |
| No. of cases | 168  | 57          | 8    | 61   | 26          | 7     |
| Age-, sex- and area-adjusted HR | 1.0 | 1.1 (0.8-1.5) | 0.8 (0.4-1.7) | 1.3 (1.0-1.7) | 1.0 (0.7-1.6) | 1.6 (0.8-3.5) |
| Multivariable HR | 1.0 | 1.1 (0.8-1.5) | 0.7 (0.4-1.5) | 1.0 (0.8-1.4) | 0.9 (0.6-1.3) | 1.2 (0.6-2.6) |
| PAF (%) | 1.1 (-4.7 to 5.4) | -0.9 (-4.5 to 0.8) | 0.7 (-5.9 to 5.5) | -1.3 (-6.2 to 1.9) | 0.4 (-1.7 to 1.3) |
| Proteinuria |     |              |      |     |              |      |
| Person-years | 80448 | 674         | 260  | 27477 | 274         | 161   |
| No. at risk  | 5930 | 52          | 21   | 2013 | 21         | 14    |
| No. of cases | 230  | 2           | 1    | 89   | 3          | 2     |
| Age-, sex- and area-adjusted HR | 1.0 | 0.9 (0.2-3.5) | 0.9 (0.1-6.5) | 1.2 (0.9-1.5) | 4.0 (1.3-12.4) | 5.0 (1.3-20.4) |
| Multivariable HR | 1.0 | 0.6 (0.2-2.6) | 0.9 (0.1-6.4) | 1.0 (0.7-1.2) | 2.5 (0.8-7.8) | 2.5 (0.6-10.3) |
| PAF (%) | -0.3 (-3.3 to 0.4) | 0.0 (-2.2 to 0.3) | -1.3 (-9.9 to 5.2) | 0.5 (-0.3 to 0.8) | 0.4 (-0.4 to 0.6) |
| Stroke      |     |              |      |     |              |      |
| Blood pressure |     |              |      |     |              |      |
| No. of cases | 64   | 59          | 35   | 20   | 18          | 27    |
| Age-, sex- and area-adjusted HR | 1.0 | 2.2 (1.5-3.1) | 2.6 (1.7-4.0) | 1.2 (0.7-2.0) | 1.5 (0.9-2.5) | 4.0 (2.5-6.2) |
| Multivariable HR | 1.0 | 2.1 (1.5-3.1) | 2.5 (1.7-3.9) | 1.2 (0.7-1.9) | 1.3 (0.8-2.3) | 3.7 (2.3-5.9) |
| PAF (%) | 14.0 (8.6 to 17.8) | 9.5 (6.3 to 11.6) | 1.3 (-3.9 to 4.4) | 2.0 (-2.3 to 4.6) | 8.8 (6.9 to 10.1) |
| Serum glucose |     |              |      |     |              |      |
| No. of cases | 125  | 22          | 11   | 57   | 6           | 2     |
| Age-, sex- and area-adjusted HR | 1.0 | 2.0 (1.3-3.2) | 2.5 (1.4-4.7) | 1.4 (1.0-1.9) | 1.2 (0.5-2.8) | 0.9 (0.2-3.8) |
| Multivariable HR | 1.0 | 1.9 (1.2-2.9) | 2.2 (1.2-4.1) | 1.2 (0.9-1.7) | 0.9 (0.4-2.1) | 0.8 (0.2-3.1) |
| PAF (%) | 4.5 (1.4 to 6.5) | 2.7 (0.6 to 3.7) | 4.5 (-3.8 to 10.4) | -0.3 (-4.2 to 1.4) | -0.3 (-4.0 to 0.6) |
| LDL-C       |     |              |      |     |              |      |
| No. of cases | 124  | 32          | 2    | 39   | 19          | 7     |
| Age-, sex- and area-adjusted HR | 1.0 | 0.8 (0.5-1.1) | 0.3 (0.1-1.0) | 1.1 (0.8-1.6) | 1.0 (0.6-1.6) | 2.0 (0.9-4.3) |
| Multivariable HR | 1.0 | 0.8 (0.5-1.2) | 0.2 (0.1-0.9) | 0.9 (0.6-1.3) | 0.8 (0.5-1.3) | 1.5 (0.7-3.2) |
| PAF (%) | -3.6 (-12.3 to 2.3) | -3.1 (-15.4 to -0.1) | -2.3 (-11.5 to 4.0) | -1.9 (-8.6 to 2.2) | 1.0 (-1.5 to 2.2) |
| Proteinuria |     |              |      |     |              |      |
| No. of cases | 155  | 2           | 1    | 62   | 2           | 1     |
| Age-, sex- and area-adjusted HR | 1.0 | 1.3 (0.3-5.4) | 1.3 (0.2-9.7) | 1.2 (0.9-1.6) | 4.0 (1.0-16.2) | 3.9 (0.5-28.1) |
| Multivariable HR | 1.0 | 0.9 (0.2-3.8) | 1.1 (0.1-7.9) | 1.0 (0.7-1.4) | 2.9 (0.7-12.0) | 1.9 (0.3-14.2) |
| PAF (%) | -0.1 (-3.1 to 0.7) | 0.0 (-2.6 to 0.4) | -0.4 (-10.9 to 7.2) | 0.6 (-0.4 to 0.8) | 0.2 (-1.3 to 0.4) |
the largest impact on CVD, especially on stroke, among the CVD risk factors (PAF = 46% for stroke)\(^25\), despite a downward trend of blood pressure levels and a decreasing prevalence of hypertension\(^26\). We also reported that the impact of diabetes on incident CVD in the community had increased from the 1990s to the 2000s, and the PAF for diabetes in 2000–2003 was especially large (16.2%) for CHD\(^3\). The present study further extended these previous findings; i.e., non-treated severe hypertension had a large impact on incident stroke and CVD (PAF = 18.0% for stroke and 13.7% for CVD), and so did non-treated severe diabetes on incident CHD (PAF = 7.1%).

More importantly, the PAF of incident CVD for blood pressure and serum glucose did not differ materially between the non-overweight high-risk group and the overweight high-risk group. We reported that the prevalence of non-overweight hypertensive persons was still higher than that of overweight hypertensive persons from 1963–1966 to 2009–2013 among both men and women in a Japanese rural community\(^26\). The risk of type 2 diabetes increases at a lower BMI in Asians than in Caucasians\(^27\) probably because East Asians have a lower insulin secretion ability than have Caucasians\(^28\).

The lack of association between LDL-C and risk of CVD in the present study was probably due to the higher proportions of intracerebral hemorrhage and lacunar infraction\(^29\) with which LDL-C levels were not associated\(^30\) and the lower proportions of atherothrombotic infraction and ischemic heart disease\(^29, 31\) with which LDL-C levels were positively associated\(^30\), compared with those in the western population. The lack of association between proteinuria and risk of CVD was due in part to the small number of CVD cases in the intermediate- and high-risk categories. The attributable risk of the non-treated high-risk group of proteinuria for incident CVD was small.

The strengths of this study include (1) the use of standardized methods for the measurement of serum lipid and risk characteristics and (2) the almost complete CVD surveillance and the high percentage of stroke events confirmed by imaging studies. This study has several limitations. First, we measured serum and proteinuria only once at the

| CHD Blood pressure | Non-overweight (BMI < 25 kg/m\(^2\)) | Overweight (BMI ≥ 25 kg/m\(^2\)) |
|-------------------|-------------------------------------|----------------------------------|
|                   | Low | Intermediate | High | Low | Intermediate | High |
| No. of cases       |     |              |     |     |              |      |
| Age-, sex- and area-adjusted HR | 1.0 | 1.4 (0.9-2.3) | 1.3 (0.7-2.5) | 1.0 (0.5-2.0) | 1.5 (0.8-2.8) | 1.5 (0.7-3.3) |
| Multivariable HR   | 1.0 | 1.5 (0.9-2.5) | 1.3 (0.7-2.5) | 0.8 (0.4-1.6) | 1.4 (0.7-2.7) | 1.4 (0.6-3.2) |
| PAF (%)            | -   | 8.0 (-2.0 to 14.0) | 2.5 (-5.2 to 6.4) | -2.0 (-13.5 to 3.8) | 2.9 (-4.5 to 6.7) | 1.7 (-4.2 to 4.3) |

| Serum glucose | Non-overweight (BMI < 25 kg/m\(^2\)) | Overweight (BMI ≥ 25 kg/m\(^2\)) |
|---------------|-------------------------------------|----------------------------------|
| No. of cases  | 69 | 7 | 5 | 22 | 7 | 0 |
| Age-, sex- and area-adjusted HR | 1.0 | 1.0 (0.5-2.2) | 1.7 (0.7-4.3) | 1.0 (0.6-1.6) | 0.3 (0.0-2.5) | 5.8 (2.6-12.5) |
| Multivariable HR | 1.0 | 1.0 (0.5-2.2) | 1.8 (0.7-4.4) | 0.8 (0.5-1.4) | 0.3 (0.0-2.0) | 4.4 (2.0-9.9) |
| PAF (%)       | -   | 0.1 (-7.3 to 3.5) | 1.9 (-1.9 to 3.5) | -4.0 (-19.6 to 5.4) | -2.4 (-22.8 to 0.5) | 4.9 (3.1 to 5.7) |

| LDL-C | Non-overweight (BMI < 25 kg/m\(^2\)) | Overweight (BMI ≥ 25 kg/m\(^2\)) |
|-------|-------------------------------------|----------------------------------|
| No. of cases | 48 | 27 | 6 | 23 | 7 | 0 |
| Age-, sex- and area-adjusted HR | 1.0 | 2.0 (1.2-3.2) | 2.6 (1.1-6.1) | 1.7 (1.0-2.7) | 1.1 (0.5-2.4) | - |
| Multivariable HR | 1.0 | 1.9 (1.1-3.0) | 2.3 (0.9-5.4) | 1.4 (0.8-2.4) | 0.9 (0.4-1.9) | - |
| PAF (%) | - | 11.2 (3.1 to 16.2) | 3.0 (-0.3 to 4.4) | 6.2 (-3.9 to 12.1) | -1.0 (-10.1 to 3.1) | - |

| Proteinuria | Non-overweight (BMI < 25 kg/m\(^2\)) | Overweight (BMI ≥ 25 kg/m\(^2\)) |
|-------------|-------------------------------------|----------------------------------|
| No. of cases | 81 | 0 | 0 | 28 | 1 | 1 |
| Age-, sex- and area-adjusted HR | 1.0 | - | - | 1.0 (0.7-1.6) | 3.0 (0.4-21.5) | 6.1 (0.8-43.8) |
| Multivariable HR | 1.0 | - | - | 0.9 (0.5-1.3) | 1.6 (0.2-11.9) | 3.7 (0.5-28.4) |
| PAF (%) | - | - | - | -4.3 (-21.2 to 6.5) | 0.3 (-3.3 to 0.8) | 0.7 (-1.0 to 0.9) |

CHD, coronary heart disease; BMI, body mass index; HR, hazard ratio; PAF, population-attributable fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol. Multivariable HRs were adjusted for age, sex, area, smoking status, alcohol intake, family history of CVD, and the above-mentioned other conventional risk factors (blood pressure, serum glucose, LDL-C, high-density lipoprotein cholesterol, triglyceride, and proteinuria).
baseline survey, which may have caused a regression dilution bias because of temporal changes and random errors in the measurement of exposure variables. Thus, the estimates we reported might have been underestimated. Second, about 67% of the participants were non-fasting, which is likely to have led to underestimation of LDL-C calculation when the Friedewald formula was used. According to a validation study conducted by our lipid reference standardization laboratory, the LDL-C level calculated using the Friedewald formula was underestimated by 4 mg/dl among non-fasting participated. Third, we could not consider the treatment status after the baseline survey in analyses. Because a part of participants did not participate in health checkups every year, we could not obtain the information whether the individuals were really left untreated (before a CVD onset) during the follow-up period. Therefore, further studies are needed to consider the effects of changes in treatment conditions on incident CVD. Fourth, although we adjusted for major covariates, there remain possible residual confounding factors such as socioeconomic status, physical activity, and nutrient intake.

Conclusion

Persons with non-treated severe hypertension and diabetes had a higher risk of CVD regardless of overweight status, and the PAF of incident CVD associated with non-treated severe blood pressure and serum glucose did not differ materially between the non-overweight and overweight groups. Our long-term observational study implies that targeting these high-risk groups is prioritized to prevent CVD regardless of overweight status.

Acknowledgements

The authors thank Late Professor Emeritus Yoshio Komachi (University of Tsukuba), Former Professor Hideki Ozawa (Oita Medical University), Former Professor Minoru Iida (Kansai University of Welfare Sciences), the Late Professor Emeritus Takashi Shimamoto (University of Tsukuba), the Late Professor Emeritus Masamitsu Konishi (Ehime University), Dr. Yoshiinori Ishikawa (Consultant at Osaka Center for Cancer and Cardiovascular Disease Prevention), Professor Yoshihiko Naito (Mukogawa Women’s University), and Professor Tomonori Okamura (Keio University) for their support in the long-term cohort study. The authors also thank the research staff at Osaka Center for Cancer and Cardiovascular Disease Prevention and the health professionals in the survey communities for their valuable assistance and expert help. The current members of the CIRCS Investigators are listed in the reference [11].

Notice of Grant Support

This study was supported, in part, by a Grant-in-Aid from the Ministry of Health, Labour and Welfare, Health and Labour Sciences Research Grants, Japan (19-F01-008 and 20-F01-002), and the Japan Society for the Promotion of Science (Scientific Research B [19H03901]).

Conflict of Interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

References

1) Li Y, Yatsuya H, Tanaka S, Iso H, Okayama A, Tsuji I, Sakata K, Miyamoto Y, Ueshima H, Miura K, Murakami Y, Okamura T and Group E-JR. Estimation of 10-Year Risk of Death from Coronary Heart Disease, Stroke, and Cardiovascular Disease in a Pooled Analysis of Japanese Cohorts: EPOCH-JAPAN. J Atheroscler Thromb, 2020; in press. doi: http://doi.org/10.5551/jat.58958
2) Satoh M, Ohkubo T, Asayama K, Murakami Y, Sugiyama D, Waki T, Tanaka-Mizuno S, Yamada M, Saitoh S, Sakata K, Irie F, Sairenchi T, Ishikawa S, Kiyama M, Okayama A, Miura K, Imai Y, Ueshima H, Okamura T and Group EfCPoCjEJR. A Combination of Blood Pressure and Total Cholesterol Increases the Lifetime Risk of Coronary Heart Disease Mortality: EPOCH-JAPAN. J Atheroscler Thromb, 2021; 28: 6–24
3) Hayama-Terada M, Muraki I, Imano H, Kiyama M, Okada T, Yamagishi K, Cui R, Ohira T, Umesawa M, Sankai T, Sato S, Kitamura A, Iso H and Investigators C. Diabetes Trend and Impact on Risk of Cardiovascular Disease in Middle-Aged Japanese People - The CIRCS Study. Circ J, 2016; 80: 2343–2348
4) Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T, Ohira T, Nakamura M, Yamagishi K, Ikeda A, Shimamoto T and Iso H. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Prev Med, 2011; 52: 381–386
5) Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H and Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int, 2006; 69: 1264–1271
6) Kobayashi A. Launch of a National Mandatory Chronic Disease Prevention Program in Japan. Disease
16) Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

17) Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwahashi Y, Kai H, Kamide K, Kanno Y, Kashiwara N, Kawanou Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohyya Y, Okura T, Rugaki H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Torniyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H and Hirawa N. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res, 2019; 42: 1235-1481.
Collaboration OiA. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev, 2008; 9 Suppl 1: 53-61

28) Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ and Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care, 2013; 36: 1789-1796

29) Tanaka H, Iso H, Yokoyama T, Yoshiike N, Kokubo Y. Cerebrovascular disease. In: Deteis R, McEwen J, Beaglehole R, editors. Oxford text book of public health: the scope of public health, 3, 4th edition Oxford, UK: Oxford University Press; 2002. p. 1193-1254

30) Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, Tanizaki Y, Ibayashi S, Iida M and Kiyohara Y. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke, 2009; 40: 382-388

31) Saito I, Folsom AR, Aono H, Ozawa H, Ikebe T and Yamashita T. Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol, 2000; 29: 837-844
## Supplemental Table 1

Hazard ratios and population-attributable fractions (95% confidence intervals) of incident cardiovascular disease (CVD) according to each risk factor category among men and women who were collected fasting blood sample and without clinical treatment.

| Risk Factor | Low | Intermediate | High | $P$ for trend |
|-------------|-----|--------------|------|--------------|
| **Blood pressure** |     |              |      |              |
| Person-years | 25051 | 9163 | 4759 |              |
| No. at risk | 1697 | 644 | 337  |              |
| No. of cases | 49 | 31 | 24  |              |
| Age-, sex- and area-adjusted HR | 1.0 | 1.4 (0.9-2.3) | 2.1 (1.3-3.5) | 0.002 |
| Multivariable HR | 1.0 | 1.6 (1.0-2.6) | 2.3 (1.3-3.9) | 0.002 |
| PAF (%) | - | 11.7 (0.7 to 18.6) | 13.1 (5.9 to 17.2) |              |
| **Serum glucose** |     |              |      |              |
| Person-years | 35299 | 2619 | 1056 |              |
| No. at risk | 2413 | 189 | 76  |              |
| No. of cases | 88  | 7  | 9   |              |
| Age-, sex- and area-adjusted HR | 1.0 | 0.7 (0.3-1.6) | 2.8 (1.4-5.6) | 0.06 |
| Multivariable HR | 1.0 | 0.6 (0.2-1.3) | 2.3 (1.1-4.8) | 0.31 |
| PAF (%) | - | -5.3 (-20.6 to 1.4) | 4.9 (0.7 to 6.8) |              |
| **LDL-C** |     |              |      |              |
| Person-years | 23796 | 12140 | 3038 |              |
| No. at risk | 1644 | 830 | 204 |              |
| No. of cases | 73  | 26 | 5   |              |
| Age-, sex- and area-adjusted HR | 1.0 | 0.7 (0.4-1.1) | 0.7 (0.3-1.7) | 0.12 |
| Multivariable HR | 1.0 | 0.6 (0.4-1.0) | 0.5 (0.2-1.3) | 0.03 |
| PAF (%) | - | -15.1 (-38.9 to -0.2) | -4.4 (-18.5 to 1.2) |              |
| **Proteinuria** |     |              |      |              |
| Person-years | 38494 | 291  | 187  |              |
| No. at risk | 2640 | 23  | 15  |              |
| No. of cases | 100 | 2  | 2   |              |
| Age-, sex- and area-adjusted HR | 1.0 | 2.0 (0.5-8.1) | 2.9 (0.7-11.9) | 0.09 |
| Multivariable HR | 1.0 | 1.6 (0.4-7.0) | 2.4 (0.6-10.4) | 0.18 |
| PAF (%) | - | 0.7 (-3.3 to 1.6) | 1.1 (-1.5 to 1.7) |              |
| **Stroke** |     |              |      |              |
| **Blood pressure** |     |              |      |              |
| No. of cases | 29  | 20 | 18  |              |
| Age-, sex- and area-adjusted HR | 1.0 | 1.5 (0.9-2.7) | 2.7 (1.5-4.9) | 0.001 |
| Multivariable HR | 1.0 | 1.8 (1.0-3.2) | 3.1 (1.7-6.0) | <0.001 |
| PAF (%) | - | 12.9 (-1.0 to 20.5) | 18.3 (10.7 to 22.4) |              |
| **Serum glucose** |     |              |      |              |
| No. of cases | 59  | 6  | 2   |              |
| Age-, sex- and area-adjusted HR | 1.0 | 1.0 (0.4-2.4) | 1.0 (0.2-4.0) | 0.98 |
| Multivariable HR | 1.0 | 0.8 (0.3-2.0) | 0.9 (0.2-4.1) | 0.72 |
| PAF (%) | - | -2.3 (-18.9 to 4.4) | -0.2 (-10.7 to 2.3) |              |
| **LDL-C** |     |              |      |              |
| No. of cases | 47  | 17 | 3   |              |
| Age-, sex- and area-adjusted HR | 1.0 | 0.7 (0.4-1.2) | 0.6 (0.2-1.9) | 0.14 |
| Multivariable HR | 1.0 | 0.7 (0.4-1.2) | 0.5 (0.2-1.8) | 0.14 |
| PAF (%) | - | -11.0 (-39.9 to 5.1) | -4.0 (-23.5 to 1.9) |              |
| **Proteinuria** |     |              |      |              |
| No. of cases | 65  | 1  | 1   |              |
| Age-, sex- and area-adjusted HR | 1.0 | 1.6 (0.2-11.8) | 2.4 (0.3-17.3) | 0.34 |
| Multivariable HR | 1.0 | 1.3 (0.2-10.1) | 1.9 (0.2-15.1) | 0.51 |
| PAF (%) | - | 0.3 (-8.0 to 1.3) | 0.7 (-4.5 to 1.4) |              |
### (Cont. Supplemental Table 1)

|                      | Low  | Intermediate | High  | $P$ for trend |
|----------------------|------|--------------|-------|---------------|
| **CHD**              |      |              |       |               |
| **Blood pressure**   |      |              |       |               |
| No. of cases         | 22   | 11           | 6     |               |
| Age-, sex- and area-adjusted HR | 1.0   | 1.2 (0.6-2.4) | 1.2 (0.5-2.9) | 0.68 |
| Multivariable HR     | 1.0   | 1.1 (0.5-2.3) | 0.8 (0.3-2.4) | 0.77 |
| PAF (%)              | -     | 1.8 (-29.6 to 16.2) | -2.8 (-35.7 to 8.9) |       |
| **Serum glucose**    |      |              |       |               |
| No. of cases         | 29   | 3            | 7     |               |
| Age-, sex- and area-adjusted HR | 1.0 | 1.0 (0.3-3.3) | 6.1 (2.6-14.0) | <0.001 |
| Multivariable HR     | 1.0 | 0.9 (0.3-3.1) | 4.5 (1.8-11.5) | 0.003 |
| PAF (%)              | - | -0.8 (-21.8 to 5.2) | 14.0 (7.9 to 16.4) |       |
| **LDL-C**            |      |              |       |               |
| No. of cases         | 27   | 10           | 2     |               |
| Age-, sex- and area-adjusted HR | 1.0 | 0.8 (0.4-1.6) | 0.8 (0.2-3.3) | 0.48 |
| Multivariable HR     | 1.0 | 0.6 (0.3-1.2) | 0.5 (0.1-2.1) | 0.10 |
| PAF (%)              | - | -19.5 (-70.4 to 4.4) | -5.6 (-41.9 to 2.7) |       |
| **Proteinuria**      |      |              |       |               |
| No. of cases         | 37   | 1            | 1     |               |
| Age-, sex- and area-adjusted HR | 1.0 | 2.6 (0.4-19.2) | 3.7 (0.5-28.0) | 0.12 |
| Multivariable HR     | 1.0 | 2.6 (0.3-20.6) | 3.2 (0.4-26.7) | 0.18 |
| PAF (%)              | - | 1.6 (-5.5 to 2.4) | 1.8 (-4.2 to 2.5) |       |

CHD, coronary heart disease; HR, hazard ratio; PAF, population-attributable fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol. Multivariable HRs were adjusted for age, sex, area, body mass index, smoking status, alcohol intake, family history of CVD, and the above-mentioned other conventional risk factors (blood pressure, serum glucose, LDL-C, high density lipoprotein cholesterol, triglyceride, and proteinuria).
## Supplemental Table 2. Hazard ratios and population-attributable fractions (95% confidence intervals) of incident cardiovascular disease (CVD) according to each risk factor category among men and women who were collected fasting blood sample and without clinical treatment, stratified by overweight status

|                      | Non-overweight (BMI < 25 kg/m²) | Overweight (BMI ≥ 25 kg/m²) |
|----------------------|-------------------------------|-----------------------------|
|                      | Low  | Intermediate | High  | Low  | Intermediate | High  |
| **CVD**              |      |              |       |      |              |       |
| Blood pressure       |      |              |       |      |              |       |
| Person-years         | 20295| 6070         | 2859  | 4756 | 3093         | 1900  |
| No. at risk          | 1375 | 437          | 203   | 322  | 207          | 134   |
| No. of cases         | 37   | 23           | 12    | 12   | 8            | 12    |
| Age-, sex- and area-adjusted HR | 1.0  | 1.7 (1.0-2.9) | 1.8 (0.9-3.4) | 1.5 (0.8-2.9) | 1.2 (0.6-2.6) | 3.3 (1.7-6.3) |
| Multivariable HR     | 1.0  | 2.1 (1.2-3.5) | 2.2 (1.1-4.4) | 1.4 (0.7-2.8) | 1.4 (0.6-3.0) | 3.0 (1.5-6.3) |
| PAF (%)              | -    | 11.3 (3.6 to 15.8) | 6.4 (1.4 to 8.9) | 3.6 (-4.0 to 7.4) | 2.0 (-5.0 to 5.1) | 7.7 (3.6 to 9.7) |
| **Serum glucose**    |      |              |       |      |              |       |
| Person-years         | 26871| 1713         | 641   | 8428 | 906          | 415   |
| No. at risk          | 1844 | 126          | 45    | 569  | 63           | 31    |
| No. of cases         | 62   | 6            | 4     | 26   | 1            | 5     |
| Age-, sex- and area-adjusted HR | 1.0  | 1.0 (0.4-2.2) | 2.1 (0.8-5.8) | 1.4 (0.9-2.2) | 0.4 (0.1-3.0) | 4.7 (1.9-11.7) |
| Multivariable HR     | 1.0  | 0.9 (0.4-2.1) | 2.0 (0.7-5.7) | 1.2 (0.7-2.0) | 0.2 (0.0-1.5) | 3.1 (1.1-8.8) |
| PAF (%)              | -    | -0.8 (-10.0 to 3.0) | 1.9 (-1.5 to 3.2) | 4.1 (-9.1 to 12.3) | -4.0 (-37.5 to 3.0) | 3.3 (0.4 to 4.3) |
| **LDL-C**            |      |              |       |      |              |       |
| Person-years         | 18588| 8528         | 2108  | 5208 | 3612         | 930   |
| No. at risk          | 1283 | 591          | 141   | 361  | 239          | 63    |
| No. of cases         | 53   | 17           | 2     | 20   | 9            | 3     |
| Age-, sex- and area-adjusted HR | 1.0  | 0.7 (0.4-1.2) | 0.4 (0.1-1.7) | 1.4 (0.8-2.4) | 0.9 (0.4-1.8) | 1.4 (0.4-4.6) |
| Multivariable HR     | 1.0  | 0.6 (0.4-1.1) | 0.3 (0.1-1.3) | 1.1 (0.6-1.9) | 0.6 (0.3-1.4) | 1.0 (0.3-3.2) |
| PAF (%)              | -    | -9.3 (-28.6 to 1.8) | -4.1 (-23.4 to 0.5) | 1.1 (-12.8 to 9.0) | -4.9 (-20.2 to 2.3) | -0.1 (-7.1 to 2.0) |
| **Proteinuria**      |      |              |       |      |              |       |
| Person-years         | 28919| 197          | 108   | 9576 | 94           | 79    |
| No. at risk          | 1990 | 16           | 9     | 650  | 7            | 6     |
| No. of cases         | 70   | 1            | 1     | 30   | 1            | 1     |
| Age-, sex- and area-adjusted HR | 1.0  | 1.4 (0.2-10.5) | 2.0 (0.3-14.9) | 1.3 (0.9-2.1) | 4.0 (0.6-28.9) | 6.4 (0.9-47.0) |
| Multivariable HR     | 1.0  | 1.3 (0.2-9.8) | 1.9 (0.2-14.5) | 1.1 (0.7-1.8) | 2.4 (0.3-19.9) | 3.8 (0.5-31.1) |
| PAF (%)              | -    | 0.2 (-4.6 to 0.9) | 0.5 (-2.9 to 0.9) | 2.5 (-13.5 to 12.6) | 0.6 (-2.4 to 0.9) | 0.7 (-1.1 to 0.9) |
| **Stroke**           |      |              |       |      |              |       |
| Blood pressure       |      |              |       |      |              |       |
| No. of cases         | 23   | 16           | 10    | 6    | 4            | 8     |
| Age-, sex- and area-adjusted HR | 1.0  | 1.9 (1.0-3.6) | 2.4 (1.2-5.1) | 1.2 (0.5-2.9) | 1.0 (0.3-2.8) | 3.4 (1.5-7.6) |
| Multivariable HR     | 1.0  | 2.1 (1.4-4.1) | 2.9 (1.3-6.3) | 1.3 (0.5-3.3) | 1.2 (0.4-3.7) | 4.1 (1.7-9.9) |
| PAF (%)              | -    | 12.7 (2.3 to 18.1) | 9.8 (3.7 to 12.6) | 2.1 (-8.2 to 6.2) | 1.0 (-9.0 to 4.3) | 9.0 (4.8 to 10.7) |
| **Serum glucose**    |      |              |       |      |              |       |
| No. of cases         | 42   | 5            | 2     | 17   | 1            | 0     |
| Age-, sex- and area-adjusted HR | 1.0  | 1.3 (0.5-3.2) | 1.7 (0.4-6.9) | 1.3 (0.7-2.3) | 0.6 (0.1-4.7) | -    |
| Multivariable HR     | 1.0  | 1.2 (0.5-3.2) | 2.0 (0.5-8.8) | 1.3 (0.7-2.4) | 0.3 (0.0-2.5) | -    |
| PAF (%)              | -    | 1.3 (-8.9 to 5.2) | 1.5 (-3.4 to 2.6) | 5.6 (-11.2 to 14.7) | -3.4 (-38.8 to 0.9) | -    |
| **LDL-C**            |      |              |       |      |              |       |
| No. of cases         | 38   | 11           | 0     | 9    | 6            | 3     |
| Age-, sex- and area-adjusted HR | 1.0  | 0.6 (0.3-1.2) | 0.9 (0.4-1.8) | 0.8 (0.3-1.9) | 1.8 (0.5-5.8) | 3.4 (0.3-1.7) |
| Multivariable HR     | 1.0  | 0.7 (0.3-1.3) | 0.8 (0.4-1.8) | 0.7 (0.3-1.7) | 1.5 (0.4-5.3) | 1.6 (0.5-7.6) |
| PAF (%)              | -    | -8.6 (-33.8 to 4.0) | -3.5 (-24.2 to 5.8) | -4.2 (-23.7 to 3.7) | -7.4 (-36.8 to 1.0) | -6.7 (-35.7 to 2.6) |
### Cont. Supplemental Table 2

|                   | Non-overweight (BMI < 25 kg/m²) | Overweight (BMI ≥ 25 kg/m²) |
|-------------------|---------------------------------|-----------------------------|
|                   | Low                             | Intermediate                | High                        | Low                             | Intermediate                | High                        |
| **Proteinuria**   |                                 |                              |                             |                                 |                              |                             |
| **No. of cases**  | 47                              | 1                            | 1                           | 18                              | 0                            | 0                           |
| **Age-, sex- and area-adjusted HR** | 1.0                             | 2.3 (0.3-17.0)               | 3.3 (0.4-24.7)              | 1.2                             | 0.7-2.0                      | -                           |
| **Multivariable HR** | 1.0                             | 1.8 (0.2-14.2)               | 2.7 (0.3-22.2)              | 1.1                             | 0.6-2.0                      | -                           |
| **PAF (%)**       | -                               | 0.6 (-5.4 to 1.4)            | 0.9 (-3.0 to 1.4)           | 2.0                             | -18.5 to 13.3                | -                           |
| **CHD**           |                                 |                              |                             |                                 |                              |                             |
| **Blood pressure**|                                 |                              |                             |                                 |                              |                             |
| **No. of cases**  | 16                              | 7                            | 2                           | 6                               | 4                            | 4                           |
| **Age-, sex- and area-adjusted HR** | 1.0                             | 1.2 (0.5-3.0)                | 0.7 (0.2-2.9)               | 1.7                             | 0.7-4.4                      | 1.4 (0.5-4.3)              |
| **Multivariable HR** | 1.0                             | 1.3 (0.5-3.2)                | 0.7 (0.2-3.3)               | 1.4                             | 0.5-3.8                      | 1.2 (0.4-3.8)              |
| **PAF (%)**       | -                               | 3.6 (-18.7 to 12.3)          | -1.8 (-26.1 to 3.6)         | 4.7                             | -12.7 to 11.3                | 1.6 (-17.7 to 7.6)          |
| **Serum glucose** |                                 |                              |                             |                                 |                              |                             |
| **No. of cases**  | 20                              | 3                            | 2                           | 9                               | 0                            | 5                           |
| **Age-, sex- and area-adjusted HR** | 1.0                             | 1.5 (0.4-5.1)                | 2.9 (0.7-12.6)              | 1.4                             | 0.7-3.2                      | -                           |
| **Multivariable HR** | 1.0                             | 1.5 (0.4-5.3)                | 2.4 (0.5-10.8)              | 1.2                             | 0.5-2.8                      | -                           |
| **PAF (%)**       | -                               | 2.5 (-10.6 to 6.2)           | 3.0 (-4.3 to 4.7)           | 3.9                             | -20.8 to 14.7                | -                           |
| **LDL-C**         |                                 |                              |                             |                                 |                              |                             |
| **No. of cases**  | 16                              | 7                            | 2                           | 11                              | 3                            | 0                           |
| **Age-, sex- and area-adjusted HR** | 1.0                             | 1.0 (2.4-2.4)                | 1.4 (0.3-6.4)               | 2.5                             | 1.2-5.4                      | 1.0 (0.3-3.6)              |
| **Multivariable HR** | 1.0                             | 0.7 (0.3-1.8)                | 0.8 (0.2-3.7)               | 1.7                             | 0.7-4.1                      | 0.6 (0.2-2.3)              |
| **PAF (%)**       | -                               | -1.7 (-43.9 to 7.9)          | -1.1 (-22.9 to 3.8)         | 12.0                            | -10.0 to 21.3                | -4.7 (-38.4 to 4.3)        |
| **Proteinuria**   |                                 |                              |                             |                                 |                              |                             |
| **No. of cases**  | 25                              | 0                            | 0                           | 12                              | 1                            | 1                           |
| **Age-, sex- and area-adjusted HR** | 1.0                             | -                            | -                           | 1.5                             | 0.7-3.0                      | 10.1 (1.4-75.2)             |
| **Multivariable HR** | 1.0                             | -                            | -                           | 1.2                             | 0.5-2.5                      | 8.1 (0.9-74.0)             |
| **PAF (%)**       | -                               | -                            | -                           | 4.1                             | -26.1 to 18.3                | 2.2 (-0.3 to 2.5)          |

CHD, coronary heart disease; BMI, body mass index; HR, hazard ratio; PAF, population-attributable fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol. Multivariable HRs were adjusted for age, sex, area, smoking status, alcohol intake, family history of CVD, and the above-mentioned other conventional risk factors (blood pressure, serum glucose, LDL-C, high density lipoprotein cholesterol, triglyceride, and proteinuria).